Neural correlates of weight gain with olanzapine

Archives of General Psychiatry

Volumn 69, Issue 12, 2012, Pages 1226-1237

  Mathews, Jose ^a   Newcomer, John W ^d   Mathews, Jennifer R ^a   Fales, Christina L ^a   Pierce, Kathy J ^a   Akers, Brandon K ^a   Marcu, Ioana ^a   Barch, Deanna M ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADULT; ANTERIOR CINGULATE; ANTICIPATION; ARTICLE; CACAO; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; EATING HABIT; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; FRONTAL CORTEX; FRUIT JUICE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; MALE; NORMAL HUMAN; OXYGEN BLOOD LEVEL; PUTAMEN; STATISTICAL SIGNIFICANCE; TOMATO; WEIGHT GAIN;

EID: 84868616853     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2012.934     Document Type: Article

References (92)

1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42.
2. Flegal KM, Williamson DF. Incident CHD and excess body weight in the US population. Obesity (Silver Spring). 2010;18(6):1069, author reply 1069-1070.
3. Archie SM, Goldberg JO, Akhtar-Danesh N, Landeen J, McColl L, McNiven J. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? Psychiatr Serv. 2007;58(2):233-239. (Pubitemid 46340468)
4. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57. (Pubitemid 38030344)
5. Baptista T, De Mendoza S, Beaulieu S, Bermúdez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord. 2004;2(4):290-307. (Pubitemid 40846902)
6. Baptista T, Zárate J, Joober R, Colasante C, Beaulieu S, Páez X, Hernández L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004;5(3):279-299. (Pubitemid 38372313)
7. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CWJr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097-1105. (Pubitemid 29466221)
8. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1-3):175-187.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. (Pubitemid 41345943)
10. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1-3):273-286.
11. Dietrich MO, Horvath TL. Feeding signals and brain circuitry. Eur J Neurosci. 2009; 30(9):1688-1696.
12. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. (Pubitemid 46762118)
13. Rolls ET. Taste, olfactory, and food texture processing in the brain, and the control of food intake. Physiol Behav. 2005;85(1):45-56. (Pubitemid 40744975)
14. Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. Cell. 2007; 129(2):251-262. (Pubitemid 46574977)
15. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317(5843):1355. (Pubitemid 47417470)
16. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25(12):1035-1059.
17. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci. 2011;15(1):37-46.
18. Petrovich GD, Holland PC, Gallagher M. Amygdalar and prefrontal pathways to the lateral hypothalamus are activated by a learned cue that stimulates eating. J Neurosci. 2005;25(36):8295-8302. (Pubitemid 41292124)
19. Rolls ET. Functions of the orbitofrontal and pregenual cingulate cortex in taste, olfaction, appetite and emotion. Acta Physiol Hung. 2008;95(2):131-164.
20. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci. 2005;6(9):691-702. (Pubitemid 43160318)
21. Kringelbach ML, O'Doherty J, Rolls ET, Andrews C. Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantness. Cereb Cortex. 2003;13(10):1064-1071. (Pubitemid 37163205)
22. Martin LE, Holsen LM, Chambers RJ, Bruce AS, Brooks WM, Zarcone JR, Butler MG, Savage CR. Neural mechanisms associated with food motivation in obese and healthy weight adults. Obesity (Silver Spring). 2010;18(2):254-260.
23. O'Doherty JP. Reward representations and reward-related learning in the human brain: insights from neuroimaging. Curr Opin Neurobiol. 2004;14(6):769-776. (Pubitemid 39576211)
24. O'Doherty JP, Deichmann R, Critchley HD, Dolan RJ. Neural responses during anticipation of a primary taste reward. Neuron. 2002;33(5):815-826. (Pubitemid 34219251)
25. Stice E, Spoor S, Bohon C, Veldhuizen MG, Small DM. Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. J Abnorm Psychol. 2008;117(4):924-935.
26. Tataranni PA, DelParigi A. Functional neuroimaging: a new generation of human brain studies in obesity research. Obes Rev. 2003;4(4):229-238. (Pubitemid 37444217)
27. Cota D, Barrera JG, Seeley RJ. Leptin in energy balance and reward: two faces of the same coin? Neuron. 2006;51(6):678-680. (Pubitemid 44374921)
28. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage. 2003;19(4):1709-1715. (Pubitemid 37025866)
29. Wise RA. Role of brain dopamine in food reward and reinforcement. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1149-1158. (Pubitemid 44874226)
30. Volkow ND, Wang GJ, Fowler JS, Logan J, Jayne M, Franceschi D, Wong C, Gatley SJ, Gifford AN, Ding YS, Pappas N. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse. 2002;44(3):175-180. (Pubitemid 34303915)
31. Wang GJ, Volkow ND, Telang F, Jayne M, Ma J, Rao M, Zhu W, Wong CT, Pappas NR, Geliebter A, Fowler JS. Exposure to appetitive food stimuli markedly activates the human brain. Neuroimage. 2004;21(4):1790-1797. (Pubitemid 38446599)
32. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Jayne M, Ma Y, Pradhan K, Wong C. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci. 2007;27(46):12700- 12706. (Pubitemid 350127825)
33. Volkow ND, Wang GJ, Telang F, Fowler JS, Thanos PK, Logan J, Alexoff D, Ding YS, Wong C, Ma Y, Pradhan K. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage. 2008;42(4):1537-1543.
34. Volkow ND, Wise RA. How can drug addiction help us understand obesity? Nat Neurosci. 2005;8(5):555-560. (Pubitemid 40594193)
35. Rothemund Y, Preuschhof C, Bohner G, Bauknecht HC, Klingebiel R, Flor H, Klapp BF. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007;37(2):410-421. (Pubitemid 47444263)
36. Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008;322(5900): 449-452.
37. Stoeckel LE, Weller RE, Cook EW III, Twieg DB, Knowlton RC, Cox JE. Widespread reward-system activation in obese women in response to pictures of highcalorie foods. Neuroimage. 2008;41(2):636-647.
38. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. (Pubitemid 29517559)
39. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
40. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
41. Roerig JL, Mitchell JE, de Zwaan M, Crosby RD, Gosnell BA, Steffen KJ, Wonderlich SA. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol. 2005;25(5):413-418. (Pubitemid 41368362)
42. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003;88(12):5875-5880. (Pubitemid 38033066)
43. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM Jr, Dananberg J. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87(6):2918-2923. (Pubitemid 34655364)
44. Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, Moles A. 30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. J Clin Psychopharmacol. 2009;29(6):576-583.
45. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic- associated adverse effects. Psychopharmacology (Berl). 2006;186(4):561-571. (Pubitemid 43855843)
46. Fernø J, Varela L, Skrede S, Vázquez MJ, Nogueiras R, Diéguez C, Vidal-Puig A, Steen VM, López M. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One. 2011;6(6):e20571.
47. Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res. 2011;216(2):561-568.
48. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18 (8):1646-1651.
49. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526.
50. Han M, Deng C, Burne TH, Newell KA, Huang XF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569-580.
51. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104 (9):3456-3459. (Pubitemid 46364180)
52. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210-251.
53. Huang XF, Han M, Huang X, Zavitsanou K, Deng C. Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res. 2006;171(2):355-362. (Pubitemid 43946500)
54. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl). 2009;207(1):119-125.
55. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. 2001;299(1):83-89. (Pubitemid 32905121)
56. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29-39.
57. Silvestre JS, Prous J. Research on adverse drug events, I: muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289-304. (Pubitemid 41044270)
58. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-BonillaML,Alvarez- Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008;99(1-3):13-22. (Pubitemid 351255577)
59. Smith RC, Rachakonda S, Dwivedi S, Davis JM. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients [published online April 2, 2012]. Psychiatry Res. doi:10.1016/j.psychres.2012.03.011.
60. Benaliouad F, Kapur S, Rompré PP. Blockade of 5-HT2a receptors reduces haloperidol- induced attenuation of reward. Neuropsychopharmacology. 2007;32 (3):551-561.
61. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment: pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-179.
62. Spitzer R, Williams J, Gibbon M, FirstM. User's Guide for the Structured Clinical Interview for DSM-IV-TR. Washington, DC: American Psychiatric Association; 1990.
63. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004; 25(1):119-142. (Pubitemid 38230109)
64. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA; for the STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79. (Pubitemid 44284089)
65. Stunkard AJ, Messick S. The Three-Factor Eating Questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71-83. (Pubitemid 15134378)
66. Cohen JD, MacWhinney B, Flatt M, Provost J. PsyScope: a new graphic interactive environment for designing psychology experiments. Behav Res Methods Instrum Comput. 1993;25(2):257-271.
67. Berns GS, McClure SM, Pagnoni G, Montague PR. Predictability modulates human brain response to reward. J Neurosci. 2001;21(8):2793-2798. (Pubitemid 32298220)
68. Critchley HD, Mathias CJ, Dolan RJ. Neural activity in the human brain relating to uncertainty and arousal during anticipation. Neuron. 2001;29(2):537-545. (Pubitemid 32206490)
69. Talairach J, Tournous J. Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System-An Approach to Cerebral Imaging. New York, NY: Thieme; 1987.
70. McDermott KB, Ojemann JG, Petersen SE, Ollinger JM, Snyder AZ, Akbudak E, Conturo TE, Raichle ME. Direct comparison of episodic encoding and retrieval of words: an event-related fMRI study. Memory. 1999;7(5-6):661-678.
71. Miezin FM, Maccotta L, Ollinger JM, Petersen SE, Buckner RL. Characterizing the hemodynamic response: effects of presentation rate, sampling procedure, and the possibility of ordering brain activity based on relative timing. Neuroimage. 2000;11(6, pt 1):735-759. (Pubitemid 30437663)
72. Ollinger JM, Shulman GL, Corbetta M. Separating processes within a trial in eventrelated functional MRI. Neuroimage. 2001;13(1):210-217. (Pubitemid 34188258)
73. Beck SM, Locke HS, Savine AC, Jimura K, Braver TS. Primary and secondary rewards differentially modulate neural activity dynamics during working memory. PLoS One. 2010;5(2):e9251.
74. Elliott R, Dolan RJ, Frith CD. Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. Cereb Cortex. 2000;10(3):308-317. (Pubitemid 30159297)
75. Gearhardt AN, Yokum S, Orr PT, Stice E, Corbin WR, Brownell KD. Neural correlates of food addiction. Arch Gen Psychiatry. 2011;68(8):808-816.
76. Highlights of prescribing information for Zyprexa. http://pi.lilly.com/ us/zyprexa-pi.pdf. Accessed June 26, 2012.
77. Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, Roelfsema F, Romijn JA, Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95(1):118-125.
78. Hays NP, Bathalon GP, McCrory MA, Roubenoff R, Lipman R, Roberts SB. Eating behavior correlates of adult weight gain and obesity in healthy women aged 55-65 y. Am J Clin Nutr. 2002;75(3):476-483. (Pubitemid 34174940)
79. Provencher V, Drapeau V, Tremblay A, Després JP, Lemieux S. Eating behaviors and indexes of body composition in men and women from the Québec family study. Obes Res. 2003;11(6):783-792. (Pubitemid 41151605)
80. Maayan L, Hoogendoorn C, Sweat V, Convit A. Disinhibited eating in obese adolescents is associated with orbitofrontal volume reductions and executive dysfunction. Obesity (Silver Spring). 2011;19(7):1382-1387.
81. Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Olié JP, Poirier MF. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol. 2009;24(5):257-264.
82. Small DM, Veldhuizen MG, Felsted J, Mak YE, McGlone F. Separable substrates for anticipatory and consummatory food chemosensation. Neuron. 2008;57(5):786-797. (Pubitemid 351343866)
83. Gottfried JA, O'Doherty J, Dolan RJ. Encoding predictive reward value in human amygdala and orbitofrontal cortex. Science. 2003;301(5636):1104-1107. (Pubitemid 37022314)
84. De Araujo IE, Rolls ET. Representation in the human brain of food texture and oral fat. J Neurosci. 2004;24(12):3086-3093. (Pubitemid 38405756)
85. Ng J, Stice E, Yokum S, Bohon C. An fMRI study of obesity, food reward, and perceived caloric density: does a low-fat label make food less appealing? Appetite. 2011;57(1):65-72.
86. Arana FS, Parkinson JA, Hinton E, Holland AJ, Owen AM, Roberts AC. Dissociable contributions of the human amygdala and orbitofrontal cortex to incentive motivation and goal selection. J Neurosci. 2003;23(29):9632-9638. (Pubitemid 37352063)
87. Hinton EC, Parkinson JA, Holland AJ, Arana FS, Roberts AC, Owen AM. Neural contributions to the motivational control of appetite in humans. Eur J Neurosci. 2004;20(5):1411-1418. (Pubitemid 39233592)
88. Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 2010;30(39):13105-13109.
89. Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebocontrolled fMRI study. Psychopharmacology (Berl). 2007;191(3):823-833. (Pubitemid 46355905)
90. Liu Y, Gao J-H, Liu H-L, Fox PT. The temporal response of the brain after eating revealed by functional MRI. Nature. 2000;405(6790):1058-1062. (Pubitemid 30447790)
91. Smeets PA, de Graaf C, Stafleu A, van Osch MJ, van der Grond J. Functional MRI of human hypothalamic responses following glucose ingestion. Neuroimage. 2005; 24(2):363-368. (Pubitemid 41359033)
92. Smeets PA, de Graaf C, Stafleu A, van Osch MJ, van der Grond J. Functional magnetic resonance imaging of human hypothalamic responses to sweet taste and calories. Am J Clin Nutr. 2005;82(5):1011-1016. (Pubitemid 43779758)